Loading stock data…
Cytokinetics (CYTK)
$80.74-1.18 (-1.44%)
Market ClosedLast close Jul 24
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cytokinetics, Incorporated in the Healthcare sector is trading at $80.74 with a market capitalization of $10.1B. Wall Street consensus targets $107.80 (20 analysts), implying a +33.5% move over the next 12 months. The stock is currently near its 52-week high of $88.31, remaining 19.7% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +33.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 34) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $19.36M↑ | $17.75M↑ | $1.94M↓ | $66.77M↑ | $1.58M |
| Gross Profit | $16.80M↑ | -$86.64M↑ | -$97.30M↓ | -$45.78M | $0 |
| Operating Income | -$183.62M↓ | -$178.37M↓ | -$166.75M↓ | -$111.51M↑ | -$155.63M |
| Net Income | -$206.03M↓ | -$183.03M↑ | -$306.18M↓ | -$134.37M↑ | -$161.38M |
Peer Comparison
JNJUNHPFE
Fundamentals
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$10.07B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
100.37%
Volume
Today's trading volume
1.20M
Recent News
All You Need to Know About Cytokinetics (CYTK) Rating Upgrade to Buy
Cytokinetics (CYTK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Think Cytokinetics (CYTK) Could Surge 30.54%: Read This Before Placing a Bet
The mean of analysts' price targets for Cytokinetics (CYTK) points to a 30.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
What This Cytokinetics Insider Sale Might Mean With the Stock Up 110%
Blum exercised options at $10.60 per share and immediately sold them at $82.02, capturing gains from a 122% stock surge over the past year. He retains 381,986 shares and maintains a 0.31% ownership stake.
Is Cytokinetics (CYTK) A Bargain On Myqorzo Approval Or Already Fully Priced?
Why the Myqorzo approvals matter for Cytokinetics stock Cytokinetics (CYTK) is in the spotlight after regulators in both the U.S. and Europe approved Myqorzo for symptomatic obstructive hypertrophic cardiomyopathy, shifting the company firmly into commercial-stage territory with an active launch underway. See our latest analysis for Cytokinetics. Despite a small pullback in the latest session, with a 1-day share price return of 1.39% and a 7-day share price return of 1.87%, Cytokinetics has...
How Myqorzo’s Commercial Launch At Cytokinetics (CYTK) Has Changed Its Investment Story
Cytokinetics has entered a new phase as a commercial-stage biotech following past FDA approval of Myqorzo for symptomatic obstructive hypertrophic cardiomyopathy and its subsequent European Commission authorization, with U.S. commercialization underway since January 2026. This shift from pure development to active commercialization, supported by early physician uptake and ongoing label-expansion efforts, materially changes how investors may view Cytokinetics’ growth profile and risk...